 SAN DIEGO, Aug. 31, 2021 PRNewswire -- Poseida Therapeutics, Inc. Nasdaq: PSTX, a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced preliminary results from its Phase 1 clinical trial of P-PSMA-101, the Companys solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer mCRPC. These data will be presented at the 6th Annual CAR-TCR Summit virtual meeting at 10:00am ET today in a presentation entitled, P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer. 